Hunan New Wellful Co., Ltd. Class A

Hunan New Wellful Co., Ltd. Class A

SSSE:600975
4.76
CNY
-0.17
(-3.45%)
-1.78EPS
6.49BMarket Cap
Mar 26Next Earn
Hunan New Wellful Co., Ltd. Class A
SSE:600975
(Shanghai Stock Exchange)

Recent

price

4.76

P/E

ratio

- -

div

yld

0.84%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.83
2.07
2.22
2.49
2.79
2.15
2.58
2.69
2.85
3.37
4.14
3.63
5.8
4.82
5.38
5.8
4.94
Revenue per Share
0.03
0.15
0.04
0.03
-0.11
0.06
0.3
0.07
-0.05
0.1
0.43
-0.44
-0.09
-1.03
0.03
-0.7
-1.73
Basic EPS, GAAP
0.04
0.09
-0.2
-0.41
-0.29
0.05
0.16
0.17
-0.12
-0.2
-0.13
-1.42
-0.25
-0.83
0.55
0.41
- -
Free Cash Flow per Basic Share
0.07
0.01
0.02
0.06
0.05
0.03
0.05
0.12
0.1
0.01
0.05
0.17
0.09
0.07
0.06
0.04
0.04
Dividend per Share
0.98
1.13
1.18
1.18
1.09
1.64
1.87
1.84
1.69
1.79
2.17
3.06
3.35
2.37
2.4
1.73
0.67
Book Value per Share
0.94
1.09
1.01
1.02
0.93
1.53
1.75
1.72
1.57
1.67
2.06
2.92
3.14
2.24
2.25
1.59
0.53
Tangible Book Value per Share
480
465
469
454
466
616
655
642
717
633
657
673
863
1,168
1,311
1,252
1,251
Basic Weighted Avg Shares
877
961
1,038
1,130
1,302
1,326
1,691
1,724
2,041
2,130
2,724
2,444
5,005
5,632
7,045
7,258
6,184
Sales/Revenue/Turnover
-4.8
6.15
0.1
-2.19
-5.79
0.39
10.07
3.15
-1.37
3.77
10.93
-2.47
2.62
-13.07
5.93
-3.72
-16.14
Operating Margin (%)
28
28
30
34
45
50
59
62
67
69
60
312
580
923
954
923
- -
Depreciation Expense
15
72
21
14
-49
37
197
45
-36
63
283
-296
-78
-1,203
39
-876
-2,168
Net Income, GAAP
24.19
3.42
6.71
6.06
- -
- -
- -
14.21
- -
3.12
- -
- -
- -
- -
5.1
- -
- -
Effective Tax Rate (%)
1.68
7.5
2.03
1.21
-3.76
2.79
11.62
2.61
-1.76
2.97
10.38
-12.12
-1.55
-21.37
0.56
-12.08
-35.06
Profit Margin (%)
216
309
225
302
150
635
749
697
558
470
508
818
420
285
715
-286
-454
Working Capital
- -
- -
- -
200
200
176
146
106
62
- -
715
2,905
5,074
6,014
6,152
5,209
5,822
LT Debt
467
540
612
622
602
1,130
1,297
1,270
1,162
1,230
1,488
2,708
2,919
3,166
3,213
2,339
989
Total Equity
-5.87
9.42
0.14
-3.44
- -
- -
- -
2.64
- -
5.59
- -
- -
- -
- -
0.58
- -
- -
Return on Invested Capital (%)
2.95
12.77
4.04
2.93
- -
- -
- -
4.06
- -
4.86
- -
- -
- -
- -
0.95
- -
- -
Return on Capital (%)
3.2
14.58
3.9
2.47
-9.21
4.68
17.15
3.7
-3.11
5.58
21.9
-15.28
-3.01
-42.33
1.31
-33.8
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,526
1,210
1,879
LT Borrowings
1,412
1,888
1,669
LT Finance Leases
4,265
4,251
4,153
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,250
1,250
1,250
Market Capitalization
6,686
5,386
6,486

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,815
2,776
2,505
Cash, Cash Equivalents & STI
782
608
658
Accounts Receivable, Net
108
95
87
Inventories
1,682
1,835
1,539
Total Current Liabilities
2,790
2,451
2,959
Payables & Accruals
- -
- -
- -
ST Debt
1,526
1,210
1,879
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.35%
14.49%
-27.21%
Free Cash Flow
118.75%
220.47%
-28.65%
Net Income, GAAP
-101.71%
-252.42%
-2,328.98%
Sales/Revenue/Turnover
21.53%
27.03%
3.02%
Total Cash Common Dividend
66.37%
42.1%
-32.79%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,430
1,803
2,038
1,774
7,045
2025
1,863
1,825
- -
1,868
7,258
2026
1,565
1,268
1,483
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
0.01
0.2
0.03
0.03
2025
0.02
0.02
- -
-0.69
-0.7
2026
-0.3
-0.29
-0.46
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.01
0.06
2025
0.02
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -
Business
Hunan New Wellful Co.,Ltd. (Shanghai Stock Exchange: 600975.SS) is a leading Chinese manufacturer and supplier of pharmaceutical preparations and medical devices, specializing in oncology, anti-infection, and nervous system therapeutics. The company offers a diverse portfolio of products including small-volume injections such as irinotecan hydrochloride for colorectal cancer treatment; tablets and capsules like entecavir for hepatitis B; and medical devices encompassing infusion sets, syringes, and blood bags, marketed under brands like New Wellful and Wellful. Founded in 1958 and headquartered in Xiangtan, Hunan province, it operates primarily in China with distribution networks serving hospitals, pharmacies, and healthcare institutions nationwide. In recent developments, Hunan New Wellful expanded its production capacity through a major green manufacturing project completed in 2024, enhancing output for key oncology drugs amid rising demand. The company formed strategic partnerships with leading pharmaceutical distributors in 2025 to bolster market penetration in tier-2 and tier-3 cities, while launching new formulations of piperacillin sodium tazobactam for anti-infection applications. Additionally, it pursued R&D collaborations with academic institutions for innovative drug delivery systems, positioning itself for growth in the competitive domestic biopharma sector.